expand/collapse risk warning

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

80% of retail investor accounts lose money when trading CFDs with this provider.

Regulator:

×
CySEC

Skilling Ltd, is regulated by the Cyprus Securities and Exchange Commission (CySEC) under CIF license No. 357/18

Continue
FSA

Skilling (Seychelles) Ltd, is authorized and regulated by the Financial Services Authority (FSA) under license No. SD042

Continue

Loading...

Moderna shares

The most popular and up-and-rising shares.

[[ data.name ]]

[[ data.ticker ]]

[[ data.price ]] [[ data.change ]] ([[ data.changePercent ]]%)

Low: [[ data.low ]]

High: [[ data.high ]]

About

History

Differences between Investing vs Trading

About

History

Differences between Investing vs Trading

Modern is a US pharmaceutical company that specialises in RNA therapeutics. The company was founded by Derrick Rossi, a 39-year-old postdoctoral fellow in stem cell biology at Stanford University. After learning about RNA-mediated immune activation in 2005, he developed a way of modifying mRNA.

In 2010, with help and investment from fellow Harvard University faculty member and entrepreneur Timothy A. Springer, Rossi launched the company ModeRNA Therapeutics. Other investors were brought onboard and following various collaborations and partnerships with other pharma companies, including AstraZeneca, ModeRNA Therapeutics became Moderna in 2018.

Today, Moderna is one of the largest pharmaceutical companies in the world and a leader in mRNA research and vaccines. And, since going public in 2018, Moderna stock has traded on the Nasdaq and the S&P 500.

Moderna stock was first available to the public in 2018 following the company’s switch from ModeRNA Therapeutics. The initial public offering (IPO) saw Moderna stock open at $23 per share. With 27 million Moderna shares sold, the IPO raised $621 million. The Moderna stock price initially fell below the IPO value of $23 per share. However, in 2020 it started to climb following the outbreak of COVID-19. With Moderna producing mRNA vaccines to help combat the virus, the company’s share price peaked at more than $449 in 2021.

Why trade the Moderna Stock price?
The Moderna stock price history shows a period of relative stability since the IPO in 2018. However, it was during the COVID-19 outbreak that Moderna shares saw their biggest gains. The impact of a move from approximately $20 per share to over $400 is not guaranteed to have a lasting effect. However, mRNA vaccines are becoming increasingly important in tackling widespread viruses and Moderna has established itself as one of the leading companies in this area.

Are trading and investing different? Yes and no. Both involve the buying and selling of financial instruments. However, it’s the way you buy and sell that differs. Investing means you own a piece of the underlying asset and, therefore, can only profit when its value increases. Trading means you’re speculating on price movements of an underlying asset, but you don’t own the asset. This means you can trade Moderna stock and take a long position (profit when its value increases) or short position (profit when its value decreases).

Loading
Swap long [[ data.swapLong ]] points
Swap short [[ data.swapShort ]] points
Spread min [[ data.stats.minSpread ]]
Spread avg [[ data.stats.avgSpread ]]
Min contract size [[ data.minVolume ]]
Min step size [[ data.stepVolume ]]
Commission and Swap Commission and Swap
Leverage Leverage
Trading Hours Trading Hours

* The spreads provided are a reflection of the time-weighted average. Though Skilling attempts to provide competitive spreads during all trading hours, clients should note that these may vary and are susceptible to underlying market conditions. The above is provided for indicative purposes only. Clients are advised to check important news announcements on our Economic Calendar, which may result in the widening of spreads, amongst other instances.

The above spreads are applicable under normal trading conditions. Skilling has the right to amend the above spreads according to market conditions as per the 'Terms and Conditions'.

device-default.png

Trade [[data.name]] with Skilling

All Hassle-free, with flexible trade sizes and with zero commissions!*

  • Trade 24/5
  • Minimum margin requirements
  • No commission, only spread
  • Fractional shares available
  • Easy to use platform

*Other fees may apply.

Sign up

FAQs

Which are the competitors of Moderna shares?

+ -

Moderna shares are one of the most popular stocks on the market today. However, there are plenty of other companies that offer similar products and services. Pfizer is a global pharmaceutical company with a long history dating back to 1849. The company offers a wide range of products, including vaccines and other biotech solutions.

Merck is another leading pharmaceutical company. It was founded in 1891 and offers a broad portfolio of products, including drugs for cancer and other diseases. Sanofi is a French multinational pharmaceutical company. It was founded in 1904 and has a strong presence in the global market.

Who owns most Moderna shares?

+ -

According to data from Nasdaq, the top three institutional investors in Moderna are Fidelity Management & Research Company, Wellington Management Company LLP, and Vanguard Group Inc. Fidelity Management & Research Company is the largest institutional investor in Moderna, with a 9.72% stake in the company. This is followed by Wellington Management Company LLP with a 7.96% stake, and Vanguard Group Inc with a 5.73% stake. These three institutional investors own a combined 23.41% of Moderna, making them the largest shareholders in the company.

Do Moderna shares pay dividends?

+ -

Moderna, Inc. (NASDAQ: MRNA) does not pay dividends on its common stock. The company has never declared or paid any dividends on its common stock. Moderna's board of directors has no current plans to declare or pay any dividends on the company's common stock in the foreseeable future.

However, that doesn't mean that investors in Moderna won't ever receive any payouts from the company. Moderna has a history of issuing special dividends and one-time payments to shareholders. For example, in December 2020, Moderna announced a special cash dividend of $0.50 per share, payable on January 15, 2021, to shareholders of record as of December

Why Trade [[data.name]]

Make the most of price fluctuations - no matter what direction the price swings and without capital restrictions that come with buying the underlying asset.

CFDs
Equities
chart-long.svg

Capitalise on rising prices (go long)

green-check-ico.svg
green-check-ico.svg
chart-short.svg

Capitalise on falling prices (go short)

green-check-ico.svg
leverage-ico.svg

Trade with leverage
Hold larger positions than the cash you have at your disposal

green-check-ico.svg
trade-ico.svg

Trade on volatility
No need to own the asset

green-check-ico.svg
commissions-ico.svg

No commissions
Just low spreads

green-check-ico.svg
risk-ico.svg

Manage risk with in-platform tools
Ability to set take profit and stop loss levels

green-check-ico.svg

Important notice

This page/website is not directed to EU clients and falls outside the European regulatory framework and is not in the scope of (among others) the Markets in Financial Instruments Directive (MiFID) II.
By continuing you acknowledge to view the content provided by Skilling (Seychelles) Limited, which is authorised and regulated by Seychelles Financial Supervisory Authority, and that your decision was made independently and at your exclusive initiative and no solicitation or recommendation has been made by Skilling or any other entity within the group.

Continue

Important notice

This page/website is not directed to EU clients and falls outside the European regulatory framework and is not in the scope of (among others) the Markets in Financial Instruments Directive (MiFID) II.
By continuing you acknowledge to view the content provided by Skilling (Seychelles) Limited, which is authorised and regulated by Seychelles Financial Supervisory Authority, and that your decision was made independently and at your exclusive initiative and no solicitation or recommendation has been made by Skilling or any other entity within the group.

Continue